Investment Crisis in Pharma: Price Controls Choke Off Innovation

The future of medical breakthroughs in the United States is under threat by a bureaucratic stroke of a pen in Washington. While the country has led the world for decades by rewarding risk-taking and innovation, the misnamed Inflation Reduction Act (IRA) of the Joe Biden era is undermining the foundations of this success. The price control mechanisms introduced by the law have caused a decline of up to 70% in investments in small-molecule drugs, sounding alarms across the market.

Biden-Era Legacy and the Flight of Capital

The Congressional Budget Office (CBO) and numerous outside experts warned that government price controls would discourage investment in new medicines, but these warnings were dismissed. Now, the "negotiation" process dictated by bureaucrats at the Centers for Medicare and Medicaid Services (CMS) is effectively a price-setting operation that is squeezing the market. As capital providers rapidly retreat from risky R&D projects with no guaranteed returns, the future of the sector is being thrust into uncertainty.

■A serious decline of up to 70% has been observed in investments for small-molecule medicines.

■Price-fixing policies enforced by CMS eliminate the manufacturers' ability to walk away from negotiations.

■Experts warn that current policies are blocking the development of future Alzheimer's or cancer treatments.

2029 CMS Rules and the Disregard for FDA Approval

The new rules being prepared for the program in 2029 could confront the sector with an even greater disaster. CMS is proposing to broaden the criteria used to group medicines for price control purposes. This change could sweep in follow-on treatments with similar chemical profiles—even those requiring separate approval from the Food and Drug Administration (FDA)—into these controls. This situation eliminates the economic motivation for developments that cost billions of dollars in Phase 3 clinical trials and new manufacturing processes.

■The new proposal aims to automatically include improved drugs with similar chemical structures under price controls.

■FDA's distinct approval process could be rendered ineffective by CMS's regulatory sleight of hand.

■The development of more practical application methods for cancer treatments could be hindered.

Drug Reformulation and Invisible Costs

Defending today's lower prices means sacrificing the innovations of tomorrow. For instance, a cancer treatment administered via intravenous infusion over hours could be transformed into an injection that takes seconds in a doctor's office. This is not merely a cosmetic change; it is a critical improvement that enhances patient access and frees up capacity. However, CMS's proposal may not view such groundbreaking improvements as "extra innovation." If investors know that a successful follow-on treatment will immediately be pulled into the older drug's price-control regime, they will have no desire to make the investment.

■Improved formulations require additional R&D costs amounting to billions of dollars.

■Price controls could block more accessible treatments for patients in rural communities.

■These policies, which stifle competition, ignore the opaque practices of insurers and pharmacy benefit managers.

From an industrial futurist perspective, this is a classic "regulation-induced supply shock" scenario. Just as China's rare earth embargoes threaten the semiconductor supply chain, Washington's price control mechanism targets the most critical link of the biotech supply chain: IP and R&D. Investors avoid uncertainty; just as TSMC calculates geopolitical risks when planning capacity, pharma firms must calculate IRA costs. This policy could slow the innovation speed of all US high-tech manufacturing, not just pharmaceuticals.